Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the feasibility of SafeLM as a primary airway device and as a conduit for intubation with and without the use of a bougie
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SafeLM as a supraglottic airway device with video capability | Experimental |
| |
| SafeLM as a supraglottic airway device without video capability | Experimental |
| |
| SafeLM as a conduit for intubation using an endotracheal tube with video capability | Experimental |
| |
| SafeLM as a conduit for intubation using a bougie with video capability | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SafeLM as a supraglottic airway device with video capability | Device | The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation. |
| Measure | Description | Time Frame |
|---|---|---|
| Intubation success rate | This is assessed by the ability of the SafeLM to achieve adequate oxygenation and ventilation via the respective procedure once the airway device is in place. | at the time of intubation |
| Measure | Description | Time Frame |
|---|---|---|
| Number of insertion attempts required to achieve effective oxygenation and ventilation | at the time of intubation | |
| Time to insertion | This is measured by the time from opening the mouth to the time of end tidal CO2 on capnography |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lauren M Nakazawa, MD | Contact | 713-500-6775 | Lauren.M.Nakazawa@uth.tmc.edu | |
| Carlos Artime, MD | Contact | 713-500-6171 | Carlos.Artime@uth.tmc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Lauren M Nakazawa, MD | The University of Texas Health Science Center, Houston | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Texas Health Science Center at Houston | Recruiting | Houston | Texas | 77030 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| SafeLM as a supraglottic airway device without video capability | Device | The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation. |
|
| SafeLM as a conduit for intubation using an endotracheal tube with video capability | Device | The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again. |
|
| SafeLM as a conduit for intubation using a bougie with video capability | Device | The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation. |
|
| at the time of intubation |
| Subjective ease of insertion of the airway device | at the time of intubation |
| Safety of the SafeLM as an SGA | This will be assessed by the number of adverse events such as airway obstruction, aspiration, and hypoxia. | at the time of intubation |
| Safety of the SafeLM as a conduit for intubation | This will be assessed by the number of adverse events such as esophageal intubation, bronchial intubation, and hypoxia during the intubation process. | at the time of intubation |